Trial
NCT06113328
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
Non-segmental Vitiligo
Intervention
MK-6194
Why stopped
Business Reasons
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-17